What are EGFR inhibitors?
EGFR inhibitors are targeted cancer medicines that block the epidermal growth factor receptor (EGFR), a protein on the surface of cells that signals them to grow and divide. This article focuses on the EGFR tyrosine kinase inhibitors (TKIs), tablets that switch off the receptor from inside the cell. They are used mainly for non-small cell lung cancer (NSCLC) with an EGFR mutation.
In some lung cancers, the EGFR gene carries a mutation that leaves the receptor permanently switched on, driving uncontrolled growth. Tablets such as osimertinib, gefitinib, erlotinib, afatinib and dacomitinib fit into the receptor’s energy-binding pocket and block the signal. For people whose cancer carries one of these mutations, the response can be dramatic, with tumours shrinking within weeks.
EGFR mutations are found in about 10-15% of lung adenocarcinomas in Europe and North America, and in a much higher proportion in East Asia. They are more common in people who have never smoked, in women, and in adenocarcinoma, but anyone with NSCLC should be tested.
A different group of EGFR-blocking drugs, the antibodies cetuximab and panitumumab, works from outside the cell and is used in bowel and head and neck cancers. These are mentioned only briefly in this article.
A brief history
Gefitinib and erlotinib were developed in the late 1990s and early 2000s, but early trials in unselected lung cancer patients showed only modest overall benefit. In 2004, researchers discovered that the people who responded remarkably well had specific EGFR mutations. This finding transformed lung cancer care, establishing routine genetic testing. Later generations of TKIs, culminating in osimertinib, were designed to overcome resistance and to reach the brain more effectively.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Targeted therapy (EGFR tyrosine kinase inhibitors) |
| Main use | Non-small cell lung cancer with an EGFR mutation |
| How it is given | Tablet taken once a day at home |
| Course length | As long as it works for advanced cancer; 3 years after surgery |
| Test needed | EGFR mutation testing on tumour tissue or blood |
| Common side effects | Acne-like rash, diarrhoea, dry skin, nail infections, mouth sores |
| Less common risks | Lung inflammation, heart effects (osimertinib) |
2. How it works
The EGFR pathway
When growth signals bind EGFR, two receptors pair up and the kinase part inside the cell is switched on, using ATP to pass the signal down a chain of proteins. Mutated EGFR is active even without a growth signal. TKIs block the ATP pocket, so the signal stops and the cancer cells stop growing and die.
Common EGFR mutations
| Mutation | Frequency | Sensitivity to TKIs |
|---|---|---|
| Exon 19 deletion | About 45% of EGFR mutations | Very sensitive |
| L858R (exon 21) | About 40% | Very sensitive |
| Uncommon mutations (G719X, L861Q, S768I) | Small proportion | Usually sensitive, especially to afatinib or osimertinib |
| Exon 20 insertions | Small proportion | Generally resistant to standard TKIs; other drugs used |
| T790M | Usually develops on treatment | Resistant to older TKIs; sensitive to osimertinib |
Generations of EGFR TKIs
| Generation | Drugs | Features |
|---|---|---|
| First | Gefitinib, erlotinib | Reversible binding |
| Second | Afatinib, dacomitinib | Irreversible binding; more side effects |
| Third | Osimertinib | Targets T790M; spares normal EGFR more; good brain penetration |
EGFR TKIs belong to the wider family of kinase inhibitors, which also includes imatinib and related drugs and TRK inhibitors.
3. Who it is for
Conditions treated
| Condition | Role of EGFR TKIs |
|---|---|
| Non-small cell lung cancer | First treatment for advanced EGFR-mutated disease; after surgery for stage IB-IIIA |
| Lung adenocarcinoma | The subtype in which EGFR mutations are most common |
| Large cell lung carcinoma | Rarely, if an EGFR mutation is found |
Settings
| Setting | Use |
|---|---|
| Advanced or metastatic | Osimertinib is the usual first choice, sometimes with chemotherapy or other drugs |
| After surgery | Osimertinib for 3 years in stage IB-IIIA disease |
| After chemoradiotherapy | Osimertinib in unresectable stage III disease |
4. Before treatment
| Step | Why it is done |
|---|---|
| Biopsy | Confirms NSCLC |
| Molecular testing | Identifies EGFR and other driver mutations |
| Liquid biopsy | Blood test for tumour DNA when tissue is limited |
| Staging scans | CT, PET-CT and brain MRI |
| Heart tracing (ECG) and heart scan | Osimertinib can affect heart rhythm and function |
| Blood tests | Liver and kidney function |
| Medicines review | Antacids and some other drugs affect absorption |
Tissue or blood testing?
Testing tumour tissue remains the gold standard, because it can look for many genetic changes at once and confirm the cancer type. However, biopsies of lung tumours can be small or difficult to obtain. A liquid biopsy looks for fragments of tumour DNA in a blood sample. A positive blood result can be acted on straight away, but a negative result does not rule out a mutation, so tissue testing may still be needed.
Why not start straight away?
Waiting for test results, which can take one to three weeks, can feel frustrating when you want treatment to begin. However, starting chemotherapy or immunotherapy before the results are known may lead to the wrong treatment. If symptoms are severe, your team can discuss options while waiting.
5. What to expect: step by step
| Step | What happens |
|---|---|
| 1. Starting tablets | Once daily at home |
| 2. Early review | After 2-4 weeks to check side effects |
| 3. Skin care | Moisturisers and sunscreen from day one |
| 4. Scans | After about 2-3 months, then every few months |
| 5. Ongoing treatment | Continued as long as the cancer is controlled |
| 6. Progression | Biopsy or blood test to look for resistance mechanisms |
| 7. Next treatment | Chosen based on the resistance found |
6. Side effects and risks
| Side effect | Notes |
|---|---|
| Acne-like rash | Face, chest and back; very common with older TKIs, milder with osimertinib |
| Dry, itchy skin | Regular moisturising helps |
| Diarrhoea | Usually mild; loperamide helps |
| Nail fold infections (paronychia) | Sore, swollen skin around nails |
| Mouth sores | Mouthwashes and soft foods |
| Eye irritation | Dry eyes, changes in eyelashes |
| Lung inflammation (interstitial lung disease) | Rare but serious; report breathlessness or cough |
| Heart rhythm changes or reduced heart function | Mainly osimertinib; monitored |
| Liver changes | Monitored with blood tests |
In the FLAURA trial, serious side effects were less common with osimertinib than with the older TKIs (34% vs 45%) (Soria et al., 2018).
Managing the rash
The rash often appears in the first few weeks. Doctors sometimes recommend antibiotics such as doxycycline to prevent or treat it, along with gentle cleansers, moisturisers and sun protection. A rash is often a sign that the drug is working, and it can usually be controlled without stopping treatment.
7. Results and outlook
| Study | Main finding |
|---|---|
| IPASS, East Asian patients with adenocarcinoma | Gefitinib was much better than chemotherapy for people with EGFR mutations but worse for those without, establishing the need for testing (Mok et al., 2009) |
| FLAURA, untreated advanced EGFR-mutated NSCLC | Osimertinib nearly doubled progression-free survival compared with older TKIs (18.9 vs 10.2 months) (Soria et al., 2018) |
| FLAURA overall survival | Median survival was 38.6 months with osimertinib compared with 31.8 months with older TKIs (Ramalingam et al., 2020) |
| ADAURA, after surgery (682 people) | At 2 years, 89% of people taking osimertinib were alive and disease-free compared with 52% taking placebo (Wu et al., 2020) |
Why testing matters
The IPASS trial showed that the same drug could help or harm depending on the tumour’s genetics. In people without an EGFR mutation, progression-free survival was longer with chemotherapy than with gefitinib (Mok et al., 2009). This is why molecular testing before treatment is essential.
8. Recovery and aftercare
Living with daily tablets
| Tip | Why |
|---|---|
| Take the tablet at the same time each day | Keeps steady levels |
| Moisturise skin twice daily | Prevents dryness and cracking |
| Use high-factor sunscreen | Skin is more sensitive to sun |
| Keep nails short and avoid biting them | Reduces nail infections |
| Report breathlessness or cough promptly | Possible lung inflammation |
| Check before taking indigestion remedies | Some reduce absorption |
When resistance develops
Almost all advanced EGFR-mutated cancers eventually become resistant. A new biopsy or blood test can show why. Possible causes include new EGFR mutations, activation of other pathways such as MET, or a change in the cancer’s appearance. In a small number of people, the cancer transforms into small cell lung cancer, which is then treated with chemotherapy such as etoposide-platinum.
Fertility and pregnancy
EGFR TKIs may harm a developing baby, so reliable contraception is needed during treatment and for a period afterwards. Because many people with EGFR-positive lung cancer are relatively young, discussing fertility and family planning early is important.
Interactions with other medicines
Some medicines and supplements change the level of EGFR TKIs in the blood. Strong acid-reducing drugs can reduce absorption of gefitinib and erlotinib, and St John’s wort can lower levels of several TKIs. Always check with your pharmacist before starting anything new, including herbal remedies.
Brain metastases
EGFR-mutated lung cancer often spreads to the brain. Osimertinib reaches the brain well, and in ADAURA, far fewer people taking it developed brain recurrence after surgery (Wu et al., 2020). Brain MRI scans are part of regular follow-up.
Coping with skin changes
Skin side effects can affect how people feel about their appearance, especially when the rash is on the face. Gentle, unperfumed skincare, light make-up designed for sensitive skin and early treatment of spots can help. Dermatology teams experienced with targeted drugs can offer further advice if the rash is troublesome.
Living well with EGFR-positive lung cancer
Many people take EGFR TKIs for years while working, travelling and enjoying family life. Patient groups specifically for EGFR-positive lung cancer offer peer support, information and advocacy. Maintaining physical activity and a healthy diet can help with energy and overall wellbeing.
EGFR antibodies in other cancers
The antibodies cetuximab and panitumumab also block EGFR, but from outside the cell. They are used in some bowel cancers without RAS mutations and in head and neck cancers, rather than for EGFR-mutated lung cancer. Their main side effect is a similar acne-like rash.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Chemotherapy | After resistance, or combined with osimertinib in some people |
| Amivantamab-based treatment | Exon 20 insertions, or after osimertinib |
| Immune checkpoint inhibitors | Generally less effective in EGFR-mutated lung cancer |
| Radiotherapy | Localised progression or symptom control |
| Surgery | Early-stage disease |
| Clinical trials | New drugs targeting resistance |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is this chemotherapy? | No, it is a targeted tablet |
| Will I lose my hair? | Hair loss is uncommon, though hair may become thinner or curlier |
| Does a rash mean it is working? | Often, but absence of rash does not mean the drug is not working |
| Can I drink alcohol? | Moderate amounts are usually fine; check with your team |
| What if I miss a dose? | Take it if within 12 hours; otherwise skip and continue as normal |
| Can I travel abroad? | Usually yes; carry enough tablets and sunscreen |
| Did smoking cause my cancer? | EGFR-mutated lung cancer often occurs in people who never smoked |
| Can I have radiotherapy at the same time? | Often, for example to a painful bone, with careful planning |
| How long will I take the tablets? | As long as they work, or 3 years after surgery |
11. Questions to ask your care team
- What EGFR mutation does my cancer have?
- Which TKI do you recommend, and why?
- Should I have chemotherapy alongside it?
- How can I prevent and manage skin side effects?
- How often will I have scans, including of the brain?
- What happens when the drug stops working?
- Are there clinical trials I could join?
Resources
- Mok, T.S. et al. (2009) ‘Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma’, New England Journal of Medicine, 361(10), pp. 947-957.
- Ramalingam, S.S. et al. (2020) ‘Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC’, New England Journal of Medicine, 382(1), pp. 41-50.
- Soria, J.C. et al. (2018) ‘Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer’, New England Journal of Medicine, 378(2), pp. 113-125.
- Wu, Y.L. et al. (2020) ‘Osimertinib in resected EGFR-mutated non-small-cell lung cancer’, New England Journal of Medicine, 383(18), pp. 1711-1723.
- National Cancer Institute (2026) Non-Small Cell Lung Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq (Accessed: October 2026).
- National Cancer Institute (2026) Osimertinib Mesylate. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/osimertinib (Accessed: October 2026).
Prepared by the editorial team, October 2026.